Physician profile
Chaplin Liu
NPI 1013029313
$738.18
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $199 · 2021: $236 · 2022: $35.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $337.22 | 2019-2022 | |
| Baxter Healthcare | $135.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.85 | 2021 | |
| Fresenius USA Marketing, INC. | $89.20 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.35 | 2022 | |
| Sanofi Pasteur INC. | $11.80 | 2020 | |
| Lilly USA, LLC | $11.17 | 2020 | |
| Akebia Therapeutics INC | $8.87 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $5.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaplin Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.